Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACUR Acura Pharmaceuticals	$0.00	$0.01	$0.00 ▼ $0.75	$13K	-2.43	2,375 shs	N/A
NVUS Novus Therapeutics	$3.08 +0.7%	$13.23	$4.50 ▼ $27.32	$4.42M	2.07	78,851 shs	194,685 shs
REXN Rexahn Pharmaceuticals		$2.06	$1.26 ▼ $4.26	$8.11M	0.98	162,968 shs	2,579 shs
TNXP Tonix Pharmaceuticals	$35.50 +0.9%	$30.54	$6.76 ▼ $130.00	$261.03M	2.05	956,778 shs	277,512 shs
TTPH Tetraphase Pharmaceuticals	$2.20	$2.20	$0.56 ▼ $8.60	$15.98M	2.33	932,542 shs	282,689 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACUR Acura Pharmaceuticals	0.00%	-92.00%	-90.00%	-98.99%	-99.27%
NVUS Novus Therapeutics	+0.65%	+12.00%	-2.84%	+8.83%	+27.80%
REXN Rexahn Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
TNXP Tonix Pharmaceuticals	0.00%	+1.75%	-8.86%	+126.98%	-60.29%
TTPH Tetraphase Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	2.6039 of 5 stars	3.5	2.0	0.0	0.0	1.0	3.3	0.6
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACUR Acura Pharmaceuticals	0.00	N/A	N/A	N/A
NVUS Novus Therapeutics	0.00	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	0.00	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,547.89% Upside
TTPH Tetraphase Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVUS, ACUR, REXN, TNXP, and TTPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	$2.48 per share	N/A
TNXP Tonix Pharmaceuticals	$10.09M	25.89	N/A	N/A	$31.82 per share	1.12
TTPH Tetraphase Pharmaceuticals	$7.38M	2.17	N/A	N/A	$6.68 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACUR Acura Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
REXN Rexahn Pharmaceuticals	-$8.64M	N/A	0.00	N/A	N/A	N/A	-72.60%	-55.68%	N/A
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)
TTPH Tetraphase Pharmaceuticals	-$70.08M	-$22.85	N/A	N/A	N/A	-798.18%	-210.86%	-121.73%	N/A

Latest NVUS, ACUR, REXN, TNXP, and TTPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACUR Acura Pharmaceuticals	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	18.78	18.78
REXN Rexahn Pharmaceuticals	N/A	3.37	3.37
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64
TTPH Tetraphase Pharmaceuticals	0.06	3.66	3.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACUR Acura Pharmaceuticals	N/A
NVUS Novus Therapeutics	N/A
REXN Rexahn Pharmaceuticals	7.49%
TNXP Tonix Pharmaceuticals	82.26%
TTPH Tetraphase Pharmaceuticals	42.29%

Insider Ownership

Company	Insider Ownership
ACUR Acura Pharmaceuticals	20.20%
NVUS Novus Therapeutics	2.20%
REXN Rexahn Pharmaceuticals	1.10%
TNXP Tonix Pharmaceuticals	0.03%
TTPH Tetraphase Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACUR Acura Pharmaceuticals	10	66.50 million	53.07 million	Not Optionable
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
REXN Rexahn Pharmaceuticals	5	4.48 million	N/A	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable
TTPH Tetraphase Pharmaceuticals	119	7.26 million	N/A	Optionable

NVUS, ACUR, REXN, TNXP, and TTPH Headlines

Recent News About These Companies

NAFDAC Seeks More Synergy with Indian Pharmaceutical Sector

March 12, 2023 | thisdaylive.comT

Infinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News Summary

February 26, 2023 | benzinga.com

Tetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test Results

August 30, 2022 | thestreet.com

Tetraphase Executive Profits Hours Before Stock Plummets

August 20, 2022 | thestreet.com

TTPH_old Historical Data

April 4, 2022 | investing.com

10 Worst NASDAQ Biotech Stocks in the Third Quarter

January 16, 2022 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVUS, ACUR, REXN, TNXP, and TTPH Company Descriptions

Acura Pharmaceuticals OTCMKTS:ACUR

$0.0002 0.00 (0.00%)

As of 07/3/2025

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Novus Therapeutics NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Rexahn Pharmaceuticals NASDAQ:REXN

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Tonix Pharmaceuticals NASDAQ:TNXP

$35.50 +0.33 (+0.94%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$35.62 +0.13 (+0.35%)

As of 07/3/2025 04:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tetraphase Pharmaceuticals NASDAQ:TTPH

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time